LUNG (pulmonx.com) Short-Term Debt to Capital

Margin risks for Pulmonx Corporation (LUNG) are tied to the pace of physician technology adoption and insurance reimbursements. The visual representation of the price for the separate_debt_short_eq metric available on the page is 0.01. Stable sales of emphysema valves support liquidity and working capital. Patient safety is guaranteed by the precise transport of consumables to medical centers, eliminating disruptions in the supply chains for pulmonology equipment.

To assess the stability of Pulmonx Corporation (LUNG), it is critical to analyze its liability structure through the ratio of short-term debt to equity. By examining this short-term debt-to-capitalization chart, an investor can determine the rate of change in financial leverage, which is particularly relevant given the company's reliance on external assemblers and the risks of disruption in outsourced production cycles.